BIOMAT Database Logo BIOMAT Database Logo

Interleukin-2-responsive wound-infiltrating lymphocytes in surgical adjuvant cancer immunotherapy. 1993

S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Medical Research Service, Wadsworth Veterans Administration Medical Center, Los Angeles, California.

Wound-infiltrating lymphocytes (WIL) were assessed in murine models of localized sarcoma and carcinoma to evaluate the role of interleukin-2 (IL-2)-responsive lymphocytes in adjuvant immunotherapy. Following tumor resection, IL-2 or diluent was injected at the surgical site for 6 days. Surgical site tissues were harvested and digested in a triple enzyme mixture, and single cell suspensions were prepared. Thy 1.2+ lymphocytes were isolated by incubating cells with monoclonal anti-Thy 1.2 antibody-coated magnetic beads. Lymphocyte-bead complexes were extracted with a magnet and cultured in medium containing IL-2 (100 units/ml) for 1-3 weeks. Perioperative IL-2 immunotherapy led to a three- to four-fold increase in WIL yield. WIL from IL-2-treated mice also demonstrated enhanced cytolysis of the autologous tumor and bound to activated endothelial cells with greater avidity than did the controls. We conclude that perioperative IL-2 therapy augments the yield, as well as the cytolytic and adhesive properties, of wound-infiltrating lymphocytes.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008809 Mice, Inbred C3H An inbred strain of mouse that is used as a general purpose strain in a wide variety of RESEARCH areas including CANCER; INFECTIOUS DISEASES; sensorineural, and cardiovascular biology research. Mice, C3H,Mouse, C3H,Mouse, Inbred C3H,C3H Mice,C3H Mice, Inbred,C3H Mouse,C3H Mouse, Inbred,Inbred C3H Mice,Inbred C3H Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions

Related Publications

S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma.
January 2003, Journal of immunotherapy (Hagerstown, Md. : 1997),
S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.
July 1986, Cancer research,
S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
January 1986, Annual review of immunology,
S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Alterations in pulmonary function in cancer patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2.
January 1990, The American review of respiratory disease,
S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes.
November 1988, Journal of the National Cancer Institute,
S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Cancer immunotherapy using tumor-infiltrating lymphocytes.
April 1992, Seminars in hematology,
S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
May 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.
March 1989, Lancet (London, England),
S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study.
June 1995, The Journal of thoracic and cardiovascular surgery,
S M Dubinett, and L Patrone, and M Huang, and J Markowitz, and W H McBride, and J S Economou, and J Tobias, and D Kelley, and D Yan, and M Seelig
Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis.
July 2004, Journal of surgical oncology,
Copied contents to your clipboard!